Ark Biosciences
Latest round
- Series D
Last raised
- Jul 2022
Total raised
- Undisclosed
Investors
- 28
About Ark Biosciences
Based in Shanghai, China and established in 2014, Ark Biosciences Inc. operates as a biopharmaceutical company that develops drug for the treatment of influenza, hepatitis B and respiratory viruses. The company's founder, Chairman and CEO, Zheng Wu, graduated from Brown University and has over 26 years of experience in drug discovery and development, having served as senior director of Roche China. The company partnered with Calibr in November 2017 to develop a new COPD drug and introduced a new anti-fibrotic drug, AK3280, from Roche in August August 2018. The company's research areas include Respiratory Syncytial Virus (RSV), Idiopathic Pulmonary Fibrosis, Hypertrophic Scars, Chronic Obstructive Pulmonary Disease (COPD) and Hepatitis B. The company's self-developed products include RSV drug Ziresovir, RSV prevention AK0610 and attention deficit hyperactivity disorder drug (ADHD) Azstarys.
Who invested in Ark Biosciences
28 investors across 5 rounds
See all investors in Ark Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ark Biosciences
Who invested in Ark Biosciences?
Ark Biosciences has 28 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ark Biosciences raised?
Ark Biosciences has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Ark Biosciences last raise money?
Ark Biosciences's most recent round on record is a Series D, in Jul 2022.
What does Ark Biosciences do?
Based in Shanghai, China and established in 2014, Ark Biosciences Inc.
Where is Ark Biosciences headquartered?
Ark Biosciences is headquartered in Shanghai, China.
Which VCs invest in companies like Ark Biosciences?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Ark Biosciences's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series D
Raising like Ark Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.